

# Synuclein- $\alpha$ (Phospho Tyr125) Rabbit pAb

CatalogNo: YP1124

## Key Features

### Host Species

- Rabbit

### Reactivity

- Human, Mouse, Rat

### Applications

- WB, IHC, IF, ELISA

### MW

- 14kD (Calculated)

### Isotype

- IgG

## Storage

**Storage\*** -15°C to -25°C/1 year (Do not lower than -25°C)

**Formulation** Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

## Recommended Dilution Ratios

**WB 1:500-2000**

**IHC 1:100-1:300**

**ELISA 1:20000**

**IF 1:50-200**

## Basic Information

**Clonality** Polyclonal

## Immunogen Information

**Immunogen** The antiserum was produced against synthesized peptide derived from human Synuclein- $\alpha$  around the phosphorylation site of Tyr125. AA range:91-140

**Specificity**

Phospho-Synuclein- $\alpha$  (Y125) Polyclonal Antibody detects endogenous levels of Synuclein- $\alpha$  protein only when phosphorylated at Y125. The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):EAYEM

---

## | Target Information

**Gene name** SNCA

**Protein Name** Alpha-synuclein

| Organism | Gene ID                 | UniProt ID               |
|----------|-------------------------|--------------------------|
| Human    | <a href="#">6622</a> ;  | <a href="#">P37840</a> ; |
| Mouse    | <a href="#">20617</a> ; | <a href="#">O55042</a> ; |
| Rat      | <a href="#">29219</a> ; | <a href="#">P37377</a> ; |

**Cellular Localization**

Cytoplasm . Membrane . Nucleus . Cell junction , synapse . Secreted . Cell projection , axon . Membrane-bound in dopaminergic neurons (PubMed:15282274) . Expressed and colocalized with SEPTIN4 in dopaminergic axon terminals , especially at the varicosities (By similarity) .


**Tissue specificity** Highly expressed in presynaptic terminals in the central nervous system. Expressed principally in brain.

## Function


Alternative products: Additional isoforms seem to exist. ,Disease: Brain iron accumulation type 1 (NBIA1, also called Hallervorden-Spatz syndrome), a rare neuroaxonal dystrophy, is histologically characterized by axonal spheroids, iron deposition, Lewy body (LB)-like intraneuronal inclusions, glial inclusions and neurofibrillary tangles. SNCA is found in LB-like inclusions, glial inclusions and spheroids. ,Disease: Defects in SNCA are a cause of autosomal dominant Parkinson disease 1 (PARK1) [MIM:168601, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. ,Disease: Defects in SNCA are the cause of Lewy body dementia (DLB) [MIM:127750]. DLB is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Presence of Lewy bodies are the only essential pathologic features. ,Disease: Defects in SNCA are the cause of Parkinson disease 4 (PARK4) [MIM:605543, 168600]. ,Disease: Deposition of fibrillar amyloid proteins intraneuronally as neurofibrillary tangles is characteristic of Alzheimer disease (AD). SNCA is a minor protein found within these deposits, but a major non amyloid component. ,Domain: The NAC domain is involved in the fibril formation. The middle region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments. ,Function: May be involved in the regulation of dopamine release and transport. Soluble protein, normally localized primarily at the presynaptic region of axons, which can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies). Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation. ,PTM: Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers. ,PTM: Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress. ,PTM: Ubiquitinated. The predominant conjugate is the diubiquitinated form. ,similarity: Belongs to the synuclein family. ,subcellular location: Membrane-bound in dopaminergic neurons. Also found in the nucleus. ,subunit: Soluble monomer which can form filamentous aggregates. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones. ,tissue specificity: Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals. ,

---


## | Validation Data



Western Blot analysis of various cells using Phospho-Synuclein- $\alpha$  (Y125) Polyclonal Antibody



Enzyme-Linked Immunosorbent Assay (Phospho-ELISA) for Immunogen Phosphopeptide (Phospho-left) and Non-Phosphopeptide (Phospho-right), using Synuclein-alpha (Phospho-Tyr125) Antibody



Immunohistochemical analysis of paraffin-embedded human tonsil. 1, Tris-EDTA, pH 9.0 was used for antigen retrieval. 2 Antibody was diluted at 1:200 (4°C overnight). 3, Secondary antibody was diluted at 1:200 (room temperature, 45min).

## Contact information

Orders: [order.cn@immunoway.com](mailto:order.cn@immunoway.com)  
 Support: [support.cn@immunoway.com](mailto:support.cn@immunoway.com)  
 Telephone: 400-8787-807(China)  
 Website: <http://www.immunoway.com.cn>  
 Address: 2200 Ringwood Ave San Jose, CA 95131 USA



Please scan the QR code to access additional product information:  
**Synuclein- $\alpha$**   
**(Phospho Tyr125)**  
**Rabbit pAb**